Conference Reports

Amsterdam, the Netherlands
23 July 2018 - 27 July 2018
Stockholm, Sweden
14 June 2018 - 17 June 2018
Chicago, Illinois
01 June 2018 - 05 June 2018
05 May 2018 - 06 May 2018
Chicago, Illinois, US
14 April 2018 - 18 April 2018
Geneva
11 April 2018 - 14 April 2018
Barcelona, Spain
21 March 2018 - 23 March 2018
Copenhagen
16 March 2018 - 19 March 2018
San Francisco, California
08 February 2018 - 10 February 2018
San Francisco, California, US
18 January 2018 - 20 January 2018
Hong Kong
20 January 2018 - 20 January 2018
Atlanta, Georgia, US
09 December 2017 - 12 December 2017
San Antonio, Texas, US
05 December 2017 - 09 December 2017
Singapore
17 November 2017 - 19 November 2017
San Diego, California, US
24 September 2017 - 27 September 2017
Madrid, Spain
08 September 2017 - 12 September 2017
Madrid
22 June 2017 - 25 June 2017
Chicago, Illinois, US
02 June 2017 - 06 June 2017
Geneva
05 May 2017 - 08 May 2017
Orlando, Florida
16 February 2017 - 18 February 2017
Amsterdam
27 January 2017 - 30 January 2017
Singapore
16 December 2016 - 19 December 2016
San Diego, California
03 December 2016 - 06 December 2016
San Antonio, Texas
06 December 2016 - 10 December 2016
Vienna
04 December 2016 - 07 December 2016
Copenhagen
07 October 2016 - 11 October 2016
Singapore
20 July 2016 - 24 July 2016
Chiang Mai
13 May 2016 - 15 May 2016
Geneva
13 April 2016 - 16 April 2016
San Francisco, CA
07 January 2016 - 09 January 2016
San Antonio, Texas, US
08 December 2015 - 12 December 2015
Orlando, Florida, US
05 December 2015 - 08 December 2015
San Antonio, TX
18 October 2015 - 21 October 2015
Vienna
25 September 2015 - 29 September 2015
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course